Plus Therapeutics Inc PSTV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PSTV is a good fit for your portfolio.
News
-
Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense
-
Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management Team
-
Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference
-
Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic
-
Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases
-
Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
-
Plus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 5, 2024
-
Plus Therapeutics Shares Jump Premarket on FDA Orphan Designation
Trading Information
- Previous Close Price
- $1.63
- Day Range
- $1.54–1.64
- 52-Week Range
- $0.97–5.09
- Bid/Ask
- $1.60 / $1.64
- Market Cap
- $6.97 Mil
- Volume/Avg
- 8,444 / 32,231
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Plus Therapeutics Inc is a clinical-stage pharmaceutical company. The company focuses on the discovery, development, and delivery of complex treatments for patients battling cancer and rare diseases. Its product pipeline includes Patented RNL and Patented DocePLUS.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 20
- Website
- https://www.plustherapeutics.com
Valuation
Metric
|
PSTV
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
PSTV
Financial Strength
Metric
|
PSTV
|
---|---|
Quick Ratio | 0.80 |
Current Ratio | 0.92 |
Interest Coverage | −33.72 |
Quick Ratio
PSTV
Profitability
Metric
|
PSTV
|
---|---|
Return on Assets (Normalized) | −80.57% |
Return on Equity (Normalized) | −483.57% |
Return on Invested Capital (Normalized) | −167.32% |
Return on Assets
PSTV
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Plbcwfnhlk | Qnxx | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Kxtgmnrz | Mczdvb | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Fjrcljnh | Kxnjvs | $99.6 Bil | |
MRNA
| Moderna Inc | Psnjbvhm | Hzzs | $38.8 Bil | |
ARGX
| argenx SE ADR | Xqgpydpt | Ldpr | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Fczkqqljl | Bdnkd | $21.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Hfblqfzjz | Ckbmdt | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Mlvwwlwh | Rxtqzf | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Kskvvqrdq | Tqmrxw | $12.4 Bil | |
INCY
| Incyte Corp | Lbqnsgfv | Bzzqlq | $11.9 Bil |